ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Advances in Multi-Modal Biomarkers for Immunotherapy Response in Non-Small Cell Lung Cancer: ctDNA, Microbiome, and Radiomics.Cancers · 2026Review
- Causal AI for cancer immunotherapy: a narrative framework review of target trial emulation, treatment-effect learning and clinical translation.Frontiers in immunology · 2026Review
- Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review).Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer immunotherapy, which leverages the immune system to combat tumor cells, has made significant advancements in oncology treatment in recent years. Yet significant challenges remain in predicting treatment responses and understanding mechanisms of resistance. Artificial intelligence (AI) and machine learning (ML) provide powerful tools to address these challenges, enabling breakthroughs in patient stratification, biomarker discovery, and treatment strategy optimization. While remarkable progress has been made in developing deep learning frameworks, including large language models (LLMs) to integrate the exponentially growing multi-omics biomedical data for cancer immunotherapy, little effort has been made to systematically and comprehensively summarize these developments or critically evaluate their translational potential. To fill these gaps, this review comprehensively examines the current landscape and future directions of AI/ML applications in cancer immunotherapy. Specifically, we discuss four key areas in AI for cancer immunotherapy: (1) patient stratification, (2) biomarker discovery, (3) treatment strategy optimization, and (4) foundation models and LLMs for cancer immunotherapy. In addition, we also critically discuss current limitations and future directions for existing AI approaches for cancer immunotherapy, highlighting the actionable insights and roadmaps to accelerate the integration of AI/ML into precision cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.